A Three-Domain Scoring System to Customize the Risk of Relapse of Differentiated Thyroid Carcinoma.
DTC
RAI
domains
post-therapeutic 131-I-WBS
pre-RAI Tg
scoring system
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
23
07
2021
revised:
23
08
2021
accepted:
24
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
the validation of a new scoring model considering the principal risk factors of differentiated thyroid cancer (DTC) relapse. we evaluated all DTC patients treated with thyroidectomy and radioactive iodine (RAI) therapy. Three domains were considered: the demographic domain (age and gender), the surgical domain (histology and the American Thyroid Association risk categories), and the RAI-related domain (pre-RAI thyroglobulin and post-therapeutic 907 DTC patients were included. The RAI-related domain was the most relevant factor in the score calculation. The tercile stratification identified significantly different survival curves: patients within the two upper terciles showed approximately 6 to 30 times more progressive risk than patients at mild risk. we have validated a three-domain scoring system and the principal impact on this score is provided by the peri-RAI findings, whose prognostic role seems to be essential in risk identification.
Identifiants
pubmed: 34503146
pii: cancers13174335
doi: 10.3390/cancers13174335
pmc: PMC8430463
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Thyroid. 2020 Jun;30(6):871-877
pubmed: 31524071
J Clin Endocrinol Metab. 2005 Mar;90(3):1440-5
pubmed: 15613412
J Clin Endocrinol Metab. 2015 May;100(5):1895-902
pubmed: 25734251
Thyroid. 2009 Nov;19(11):1167-214
pubmed: 19860577
J Clin Endocrinol Metab. 2013 Mar;98(3):1163-71
pubmed: 23430789
Thyroid. 2021 Jan;31(1):3-7
pubmed: 32900277
Thyroid. 2016 Mar;26(3):373-80
pubmed: 26914539
J Clin Epidemiol. 2020 Jul;123:180-188.e2
pubmed: 32145366
Sci Rep. 2016 Jun 08;6:27086
pubmed: 27272218
Front Endocrinol (Lausanne). 2019 Mar 12;10:146
pubmed: 30930852
Thyroid. 2020 May;30(5):713-719
pubmed: 31973653
Clin Nucl Med. 2013 Jan;38(1):18-24
pubmed: 23242039
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):547-553
pubmed: 31707429
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):822-830
pubmed: 32955602
J Nucl Med Technol. 2014 Sep;42(3):170-80
pubmed: 25190758
Int J Mol Sci. 2017 Jun 17;18(6):
pubmed: 28629126
Cancers (Basel). 2020 Mar 08;12(3):
pubmed: 32182688
Semin Nucl Med. 2006 Jul;36(3):194-205
pubmed: 16762610
Endocr Relat Cancer. 2016 Nov;23(11):R499-R515
pubmed: 27578827
Cancers (Basel). 2020 Sep 12;12(9):
pubmed: 32932713
J Nucl Med. 2009 Jan;50(1):18-23
pubmed: 19091884
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759760
J Endocrinol Invest. 2010 Feb;33(2):83-7
pubmed: 19636213
Endocrinol Metab Clin North Am. 2019 Mar;48(1):23-35
pubmed: 30717905
Qual Life Res. 2015 Feb;24(2):325-38
pubmed: 25106505
Endocr Relat Cancer. 2017 Sep;24(9):485-493
pubmed: 28696209
Endocrine. 2018 Sep;61(3):506-510
pubmed: 29948933
Eur J Endocrinol. 2017 May;176(5):497-504
pubmed: 28137736
Curr Opin Oncol. 2015 Jan;27(1):1-7
pubmed: 25310641
J Nucl Med. 2005 Sep;46(9):1473-80
pubmed: 16157530
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Thyroid. 2019 Apr;29(4):461-470
pubmed: 30900516
Minerva Endocrinol. 2020 Nov 19;:
pubmed: 33213117
Thyroid. 2015 Jan;25(1):125-32
pubmed: 25369076